Dokumentdetails
ID

doi:10.1186/s43046-024-00220-8...

Autor
Kouchaki, Hosein Kamyab, Parnia Darbeheshti, Farzaneh Gharezade, Arezou Fouladseresht, Hamed Tabrizi, Reza
Langue
en
Editor

Springer

Kategorie

Medicine & Public Health

Jahr

2024

Auflistungsdatum

01.05.2024

Schlüsselwörter
mir-939 cancer diagnostic prognostic therapeutic target cancer mir-939
Metrisch

Zusammenfassung

Background MicroRNAs (miRNAs or miRs) are highly conserved non-coding RNAs with a short length (18–24 nucleotides) that directly bind to a complementary sequence within 3′-untranslated regions of their target mRNAs and regulate gene expression, post-transcriptionally.

They play crucial roles in diverse biological processes, including cell proliferation, apoptosis, and differentiation.

In the context of cancer, miRNAs are key regulators of growth, angiogenesis, metastasis, and drug resistance.

Main body This review primarily focuses on miR-939 and its expanding roles and target genes in cancer pathogenesis.

It compiles findings from various investigations.

MiRNAs, due to their dysregulated expression in tumor environments, hold potential as cancer biomarkers.

Several studies have highlighted the dysregulation of miR-939 expression in human cancers.

Conclusion Our study highlights the potential of miR-939 as a valuable target in cancer diagnosis, prognosis, and treatment.

The aberrant expression of miR-939, along with other miRNAs, underscores their significance in advancing our understanding of cancer biology and their promise in personalized cancer care.

Kouchaki, Hosein,Kamyab, Parnia,Darbeheshti, Farzaneh,Gharezade, Arezou,Fouladseresht, Hamed,Tabrizi, Reza, 2024, miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review, Springer

Dokumentieren

Öffnen

Teilen

Quelle

Artikel empfohlen von ES/IODE AI

Exploring Scalability in Large-Scale Time Series in DeepVATS framework
series visual scalability deep learning embeddings time module
Detection of a major Lynch Syndrome-causing MLH1 founder variant in a large-scale genotyped cohort
lynch syndrome mismatch repair deficiency biobank genotype association personalized medicine identified genotyped individuals mlh1 founder cancer variant